Brooke Worthing

Brooke Worthing is a healthcare communications professional working with the NIH’s Intramural Research Program. Brooke partners with individuals at the IRP to promote the innovative work being done within the organization to both internal and external audiences. Brooke has experience in many areas of the healthcare industry including disease state awareness communications, product communications, corporate communications, and patient advocacy. She particularly enjoys learning and writing about breakthrough innovations with the potential to make a real difference in the lives of patients suffering with serious diseases. When she isn’t busy reading and writing about what’s new in the healthcare and science, Brooke enjoys listening to podcasts, trying new restaurants and traveling.

Posts By This Author

Teaching an Old Vaccine New Tricks to Thwart Tuberculosis

The IRP’s Mario Roederer and Robert Seder Discuss the Science Behind the Headlines

Mycobacterium tuberculosis bacteria, the cause of tuberculosis

Some say that if something’s not broken, then don’t fix it, but that doesn’t mean there’s no room for improvement. At least, those were the thoughts of IRP senior investigators Mario Roederer, Ph.D., and Robert Alan Seder, M.D., who recently found that the century-old tuberculosis (TB) vaccine is far more effective when administered via injection into a vein (IV) rather than into the skin, which has long been the standard way it is given. This major breakthrough received extensive media coverage, including a story in the New York Times. We went Behind the Headlines to get the inside scoop on this potentially life-saving discovery.

IRP’s Michael Lenardo Elected to National Academy of Sciences

NIH Researcher Recognized for Enhancing the Molecular Understanding of Immune Responses

Dr. Michael Lenardo

The National Academy of Sciences (NAS), established in 1863, is comprised of the United States’ most distinguished scientific scholars, including nearly 500 Nobel Prize winners. Members of the NAS are elected by their peers and entrusted with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to advance innovations in the United States.

IRP senior investigator Michael Lenardo, M.D., is one of four IRP researchers elected to the NAS over the past two years. At the NIH, Dr. Lenardo serves as Chief of the Molecular Development of the Immune System Section at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), where he studies how the cells in the immune system mount protective responses to various pathogens, including viruses and bacteria. A major focus of Dr. Lenardo’s work is the investigation of genetic abnormalities in the immune system, which have the potential to cause life-threatening diseases.

Extreme Obesity Shaves Years Off Life Expectancy

Four Questions with Dr. Cari Kitahara

a man with obesity walking in the park

As happens with every new year, many people around the world woke up on January 1 committed to improving their health through eating well and exercising. These lifestyle changes have the potential to significantly improve the well-being of the 32 percent of American adults who are overweight and the 40 percent who are obese. Due to the staggering number of individuals struggling with obesity, as well as its serious health consequences, the condition has long been a main priority for researchers at the NIH. As a result of this focus, investigators have made significant strides in identifying biological signals that trigger hunger, understanding genetic influences that play a role in weight gain, and uncovering environmental and behavioral factors that influence obesity.

A Country-Spanning Cancer Collaboration

Scientific Team-Up Identifies Source of Tumor Drug Resistance

acute myeloid leukemia cells

It’s an unfortunate reality that nearly everyone knows somebody whose life has been affected by cancer. However, a discovery by two researchers who met by chance years ago might one day help more cancer patients overcome their disease. Two scientific teams led by the IRP’s Craig Thomas, Ph.D., a group leader at the NIH’s National Center for Advancing Translational Sciences (NCATS), and Daniel Starczynowski, Ph.D., of Cincinnati Children’s Hospital Medical Center, recently published a study describing a possible breakthrough in the fight against acute myeloid leukemia (AML), a form of cancer responsible for nearly 11,000 deaths per year in the United States.

Three-Armed Antibody Could Offer Defense Against AIDS

Four Questions with Dr. John Mascola

HIV-infected T cell

The disease known as human immunodeficiency virus, or HIV, attacks and destroys cells vital to the immune system. This leaves the millions of people living with HIV less able to fight other infections and can lead to an extremely severe form of immune system deficiency called acquired immunodeficiency syndrome (AIDS), which was responsible for nearly 770,000 deaths in 2018 alone. As of 2019, there are approximately 37.9 million people around the world living with HIV/AIDS.

Although HIV/AIDS has been recognized as a serious public health crisis, finding effective treatments, or a vaccine to prevent infection in the first place, is not a simple task. The HIV virus has many different types and strains — similar to the flu — which makes developing vaccines and treatments extremely challenging, as the virus is constantly changing. At the NIH, there are a number of ongoing collaborative research projects aimed at providing new options for those diagnosed with HIV/AIDS and those at risk for contracting the virus in the future.

A New Understanding of What’s Living on Your Skin

Five Questions with Dr. Heidi Kong and Dr. Julia Segre

microbes within a human body

When people think of skin health, they often think of protecting it from harmful UV rays or finding ways to avoid the fine lines and wrinkles that often come with aging and sun exposure. However, there are many factors and illnesses that impact skin health, including eczema, a chronic condition that affects tens of millions of Americans and causes the skin to become red and so itchy that it can interfere with patients’ sleep.

To combat such conditions, IRP researchers have spent decades investigating what causes them in humans through techniques such as immunology, genetics, molecular biology, and structural biology. In a 2014 study of healthy volunteers, IRP investigators Julia Segre, Ph.D., and Heidi Kong, M.D., M.H.Sc., used the latest genomic techniques to investigate the collection of microorganisms living on healthy human skin, known as the skin microbiome, in an attempt to understand how this collection of bacteria, fungi, and viruses may contribute to skin health. From their interdisciplinary research, the team was able to show that the array of microbes living on human skin is extremely diverse, varying greatly from individual to individual and between different areas of the body. This research opened doors for additional studies exploring how changes in the skin microbiome contribute to both common and rare skin diseases.

Antibiotics Could Assist Liver Cancer Care

Four Questions with Dr. Tim Greten

medications

There are over 100 different types of cancer, with liver, breast, and colon cancers among the most common. At the NIH, researchers across the organization have long been committed to furthering cancer research in an effort to increase the number of cancer survivors. They consistently push the boundaries of this field each day in the hopes that their work could lead to better diagnoses, better treatment, and better outcomes for cancer patients.

A 2018 study by IRP senior investigator Tim Greten, M.D., and his IRP colleagues did just that and more. Their research pushed the norms of cancer research by studying how a treatment as simple as antibiotics affects cancerous liver tumors. By utilizing antibiotics to wipe out the collection of microorganisms living in the digestive tracts of mice — known as the gut microbiome — the team identified a link between the gut microbiome and the behavior of the liver’s immune cells, which play a role in defending the organ against cancer. The IRP team ultimately showed that antibiotic treatment reduced the development of liver tumors in these ‘germ-free’ mice, and it also reduced the likelihood that tumors in other areas of the body would metastasize — or spread — to the animals’ livers, a finding that could one day prove beneficial to future cancer patients.

Genes Contribute to Population-Based Differences in Antidepressant Response

5 Questions with Dr. Francis McMahon

doctor examining African American patient

Depression is one of the most common mental health conditions in the U.S., affecting nearly seven percent of American adults each year. With the increasing social and economic pressures of the modern world likely contributing to depressive symptoms, it is more important now than ever to study depression and the factors that contribute to recovery.

A number of variables contribute to an individual’s overall mental health and response to treatment, including elements of nature and nurture that have long been studied at the NIH. In a 2013 study, researchers led by IRP senior investigator Francis McMahon, M.D., set out to understand the complex genetic factors that he believed might help explain why antidepressants are less effective for African Americans with depression than for other populations. His research revealed that differences in socioeconomics and health explained most of those differences in antidepressant response, and the remaining differences were explained by differences in genetic ancestry, rather than self-reported race. The discovery that genetics play a role in this health disparity could help close the gap and improve depression treatment for African Americans.

IRP’s Michael Gottesman Elected to National Academy of Sciences

NIH Investigator Recognized for Insights into Drug Resistance in Cancer

Dr. Michael Gottesman

The National Academy of Sciences, a private society established in 1863, is made up of the United States’ most distinguished scientific scholars, including nearly 500 members who have won Nobel Prizes. Members of the NAS are elected by their peers and charged with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to further scientific innovation in the U.S.

IRP Senior Investigator Michael Gottesman, M.D., is one of four IRP researchers who were elected to the Academy over the past two years. At the NIH, Dr. Gottesman plays two very different but equally important roles, serving as Deputy Director for Intramural Research while also leading the Laboratory of Cell Biology at the National Cancer Institute (NCI).

Yoga Helps Pain and Brain

Five Questions with Dr. Catherine Bushnell

woman practicing yoga

Yoga is all the rage these days, with millions of people taking part in the practice for relaxation, meditation, and increasing flexibility and muscle strength. However, the benefits of yoga go beyond what most might think. In fact, the mind-body practice of yoga could have a significant impact on the lives of those living with chronic pain, a condition that affects tens of millions of Americans.

In the past, doctors often prescribed opioids to treat chronic pain. However, research has shown that people with chronic pain have anatomical and neurochemical alterations in the brain that make them less responsive to opioids. In addition, both the medical and political systems are currently contending with a public health crisis stemming from the over-use of opioid pain medications. As a result, researchers have been working to identify ways to better manage chronic pain, particularly without the use of medication.

This page was last updated on Thursday, January 20, 2022